Disease Info Card

Uterine Corpus Sarcoma

Information about Uterine Corpus Sarcoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Uterine Corpus Sarcoma

Most recent studies have shown that Uterine Corpus Sarcoma shares some biological mechanisms with adenocarcinoma, carcinoma, carcinosarcoma, endometrial-carcinoma, endometrial-neoplasms, endometrial-polyp, endometrial-stromal-sarcoma, hemorrhage, leiomyosarcoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-tumor-of-cervix, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, ovarian-neoplasm, sarcoma, uterine-cervical-neoplasm, uterine-fibroids, uterine-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Uterine Corpus Sarcoma, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Drug Resistance, Fertilization, Gene Silencing, Immune Response, Localization, Menarche, Menopause, Menstruation, Mismatch Repair, Mitosis, Pathogenesis, Secretion, Transport, Tube Formation

Quite a number of genes have been found to play important roles in Uterine Corpus Sarcoma, such as ABCB1, DES, DST, EGFR, ESR1, KIT, MID1, MME, PGPEP1, PGR, SLC25A5, TBC1D9, TMEM37, TP53, TP63, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.